The former group director of virology at Connecticut-based Bristol-Myers Squibb, Robert Hindes, MD, now serves Trek Therapeutics as chief medical officer. One of the company's co-founders, Robert Hindes, MD, manages Trek’s clinical strategy development. In February of 2017, Trek Therapeutics gave an oral presentation to the Asian Pacific Association for the Study of the Liver regarding its Faldaprevir (FDV), Ribavirin (RBV), and TD-6450 Phase 2a trial results.
Dr. Tarek I. Hassanein hosted the presentation, which focused on the evaluation of all-oral combinations of the three previously mentioned drugs as a treatment method for hepatitis C (HCV). He expanded on Trek’s “Development of an Affordable and Accessible HCV Treatment: Phase 2a Study” abstract. A blind, randomized trial that examined 16 subjects with genotype 4 HCV, without cirrhosis, the trial achieved sustained viral response (SVR) for 12 weeks in all subjects. The trial incorporated a combination of 60 or 120 mg of TD-6450, alongside RBV and 120 mg of FDV.
Trek Therapeutics is now conducting Phase 2a trials to evaluate the effectiveness of further combinations of the three drugs in patients with genotype 1b HCV.
Dr. Tarek I. Hassanein hosted the presentation, which focused on the evaluation of all-oral combinations of the three previously mentioned drugs as a treatment method for hepatitis C (HCV). He expanded on Trek’s “Development of an Affordable and Accessible HCV Treatment: Phase 2a Study” abstract. A blind, randomized trial that examined 16 subjects with genotype 4 HCV, without cirrhosis, the trial achieved sustained viral response (SVR) for 12 weeks in all subjects. The trial incorporated a combination of 60 or 120 mg of TD-6450, alongside RBV and 120 mg of FDV.
Trek Therapeutics is now conducting Phase 2a trials to evaluate the effectiveness of further combinations of the three drugs in patients with genotype 1b HCV.